AstraZeneca’s (AZN) Buy Rating Reiterated at Jefferies Financial Group

Jefferies Financial Group reissued their buy rating on shares of AstraZeneca (LON:AZN) in a report issued on Wednesday,Digital Look reports. They currently have a £175 price objective on the biopharmaceutical company’s stock.

Other research analysts also recently issued research reports about the stock. Berenberg Bank restated a “buy” rating and set a £160 price target on shares of AstraZeneca in a report on Thursday, September 3rd. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating and issued a £115 price objective on shares of AstraZeneca in a report on Wednesday, September 2nd. Finally, Citigroup increased their target price on shares of AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a research report on Tuesday, July 28th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of £151.14.

AstraZeneca Price Performance

Shares of AZN opened at £117.40 on Wednesday. The firm has a market cap of £182.08 billion, a PE ratio of 17.58, a PEG ratio of 0.86 and a beta of 0.20. The firm’s 50 day moving average price is £123.23 and its 200 day moving average price is £135.46. The company has a debt-to-equity ratio of 64.10, a quick ratio of 0.59 and a current ratio of 0.89. AstraZeneca has a twelve month low of £107.84 and a twelve month high of £157.32.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.